Skip to main content
. 2020 Apr 13;9(4):952. doi: 10.3390/cells9040952

Figure 5.

Figure 5

Effect of BLR200 on gemcitabine distribution. Gemcitabine (A) and the dFdU metabolite (B) were measured by HPLC–MS analysis in plasma and tumors of mice bearing FC1199 orthotopic tumors, treated or not with BLR200. Data are the ratio between tumor (T) and plasma (P) concentration, 30 min and 1 h after gemcitabine administration (mean ± SEM, n = 4).